anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
A 77-year-old woman was referred to our hospital due to left upper abdominal pain, appetite loss and body weight loss for 1 month. Her past medical history was diabetes and intraductal papillary mucinous neoplasms (IPMNs). She had no fever and physical examination revealed mild tenderness in the left upper abdomen. Blood tests showed elevated inflammatory response with normal serum pancreatic enzymes. Contrast-enhanced CT showed marked swelling of the pancreatic tail, increased peripancreatic fatty tissue density, multiple IPMNs and obscuration of the enlarged main pancreatic duct at the tail. EUS showed there was no obvious mass in the pancreas and protein plug was suspected in the main pancreatic duct. EUS-FNA was performed and pathology showed no malignancy. ERCP showed discharge of purulent pancreatic fluid from the major duodenal papilla and stenosis of the main pancreatic duct at the tail. The culture of the purulent pancreatic fluid revealed Streptococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa, leading to diagnosis of acute obstructive suppurative pancreatic ductitis (AOSPD). Endoscopic nasopancreatic drainage and antimicrobial treatment were started. The inflammatory response improved rapidly and the patient was discharged 30 days after admission. To our knowledge, this is the second reported case of spontaneous AOSPD associated with IPMNs.
Sym015 was tested in four dose titration cohorts. Patients in this cohort received 6 mg/kg. A substitute or an additional dose level could potentially be evaluated.
During IVF treatment all ultrasound examinations will use standard 2D ultrasound. Timing of hCG injection and oocyte collection will be based on follicle diameter.
The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk \> 1:8 must start low-dose aspirin treatment immediately. Participants with a risk \< 1:8 will be excluded.
The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
The invention discloses a compound frusemide injection and its preparation method and use. The compound frusemide injection comprises, by weight, 5-20 parts of difluoxacin hydrochloride, 0.25-5 parts of frusemide, 50-300 parts of ethanol, 50-300 parts of propylene glycol and 400-900 parts of injection water. The preparation method comprises the following steps of orderly and gradually dissolving the above ingredients, adjusting a pH value to 9.5-10.5 by hydrochloric acid or sodium hydroxide, and adding injection water into the mixture until the number of the total parts is 1000. The compound frusemide injection is stable and has a wide antimicrobial spectrum, fast and substantial curative effects and high bioavailability. An experiment proves that through combination of difluoxacin hydrochloride and frusemide, the curative effects are improved. The compound frusemide injection has a wide clinical application range, can be used as a first-choice drug for treating piglet edema diseases, can improve a piglet survival rate and can reduce incidence of diseases.
PURPOSE:An substantially nontoxic anticarious agent, containing a gallic acid as an active ingredient and having extremely effective, specific and lasting multiplication inhibitory effect on Streptococcus mutans which is a causative bacterium of dental caries. CONSTITUTION:An anticarious agent containing a compound expressed by formula I (R1 and R2 are H, OH or F, preferably OH or F; R3 is H, CH3, C2H5, C3H7, C4H9 or formula II) and a pharmaceutically acceptable acid addition salt or base salt thereof as an active ingredient. The above-mentioned anticarious agent is capable of extremely effectively and specifically suppressing or inhibiting multiplication of Streptococcus mutans which is a causative bacterium of dental caries. Furthermore, if the agent is removed after exposure to the bacterium for a short time, the above-mentioned effect sustains. Thereby the agent can be suitably used as an oral composition for preventing and inhibiting dental caries or drink or food for inhibiting and preventing the dental caries by adding the agent in a concentration of about 0.01-5wt% to an oral composition, e.g. dentifrice, gargle, troche, etc., ordinary drink or food.
FIELD: medicine, endocrinology, pharmacy. SUBSTANCE: invention relates to antidiabetic agent that can be used in treatment of patients with diabetes mellitus. Invention proposes to use the known agent, i. e. the Kuril Islands' bush tea as antidiabetic agent for treatment and prophylaxis of patients with diabetes mellitus by new prescription. Agent shows the expressed hypoglycaemic effect, protective effect on insular tissue of pancreas, antioxidant properties, favorable effect on lipid metabolism and functional state of liver and kidneys. This phytoextract can be recommended in complex treatment of patients with diabetes mellitus. EFFECT: enhanced antidiabetic effectiveness of agent. 1 cl, 5 tbl, 1 dwg
###  Patients Not Currently Taking Immediate-Release Nevirapine

Patients must initiate therapy with one 200 mg tablet of immediate-release nevirapine daily for the first 14 days in combination with other antiretroviral agents. The 14-day lead-in period with nevirapine 200 mg daily dosing must be strictly followed (the lead-in period has been observed to decrease the incidence of rash), followed by one 400 mg tablet of nevirapine extended-release once daily [see Dosage and Administration (2.5) and Warnings and Precautions (5.2)]. If rash persists beyond the 14-day lead-in period with immediate-release nevirapine, do not begin dosing with nevirapine extended-release tablets. The lead-in dosing with 200 mg once daily immediate-release nevirapine should not be continued beyond 28 days, at which point an alternative regimen should be sought.

###  Switching Patients from Immediate-Release Nevirapine to Nevirapine Extended-Release Tablets

Patients already on a regimen of immediate-release nevirapine twice daily in combination with other antiretroviral agents can be switched to nevirapine extended-release tablets 400 mg once daily without the 14-day lead-in period. Patients already on a regimen of immediate-release nevirapine twice daily who switch to nevirapine extended-release tablet therapy should continue with their ongoing clinical and laboratory monitoring.
This study is a Randomized, Open-label, Single-dose, Single-center, two-sequence, two- stage Phase I Trial. 16 Healthy Volunteers will be enrolled and Randomized into two arms. 8 Healthy Volunteers were in each arm. Arm A：Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet. Arm B: Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state. During the trial, Blood samples were collected.
ZELAPAR should not be used at daily doses exceeding those recommended (2.5 mg/day) because of the risks associated with non-selective inhibition of MAO [see Drug Interactions (7.3) and Clinical Pharmacology (12.2)].

The selectivity of ZELAPAR for MAO-B may not be absolute even at the recommended daily dose of 2.5 mg daily. The selectivity of MAO-B inhibitors typically decreases, and it is ultimately lost as the dose is increased beyond recommended doses. Hypertensive reactions associated with ingestion of tyramine-containing foods have been reported even in patients taking the recommended daily dose of swallowed selegiline, a dose which is generally believed to be selective for MAO-B. Selectivity for MAO-B inhibition is gradually lost with increasing daily doses. An increase in tyramine sensitivity for blood pressure responses appears to begin at a dose of 5 mg ZELAPAR daily [see Drug Interactions (7.5)]. However, the precise dose at which ZELAPAR becomes a non-selective inhibitor of all MAO enzymes in individual patients is unknown.

Reports of hypertensive reactions have occurred in patients who ingested tyramine-containing consumables (i.e., food or drink) while receiving swallowed selegiline at the recommended dose (a dose believed to be relatively selective for MAO-B).

The safe use of ZELAPAR at doses above 2.5 mg daily without dietary tyramine restrictions has not been established. 

A pharmacodynamic study showed increased tyramine sensitivity for increasing blood pressure and decreased selectivity for MAO-B with dosing above the recommended level (2.5 mg daily) [see Clinical Pharmacology (12.2)].

Uncontrolled hypertension has been reported when taking the recommended dose of swallowed selegiline and a sympathomimetic medication (ephedrine). 

After starting ZELAPAR, monitor patients for new onset hypertension or exacerbation of hypertension that is not adequately controlled.
FIELD: medicine, ophthalmology. SUBSTANCE: invention proposes a novel agent for treatment of traumatic conjunctivitis, blepharoconjunctivitis and keratitis. This agent is the polyvalent purified liquid pyobacteriophage. An agent shows not only the known antibacterial properties but anti-inflammatory and reparative properties also, it increases immunoglobulin concentration in tear and amount of active neutrophiles. Invention ensures to broaden the arsenal of drugs used for treatment of patients with traumatic bacterial conjunctivitis, blepharoconjunctivitis and keratitis. An agent does not cause allergic responses and irritation of eye mucosa. EFFECT: enhanced effectiveness of an agent, absence of adverse effects.
The invention relates to a nursing agent for cleaning and nourishing private parts of middle-aged and elderly people. The nursing agent is prepared from effective sterilization components such as enteromorpha prolifera polysaccharide, an alga activation factor, enteromorpha prolifera mucinous protein and honeysuckle extracts as a formula system and plant essence such as lemon extract by a certain process. The nursing agent is suitable for the middle-aged and elderly people suffering from colpoxerosis, fungus-caused urethritis, foreign odor at private parts and private part tinea and can kill the possibly existing pathogenic bacteria. In addition, the nursing agent has the functions of peculiar smell dispelling and private part cleaning and moistening. The nursing agent belongs to the technical field of sanitation and sterilization. Various types of the existing products for treating fungus-caused urethritis, foreign odor at private parts and private part tinea have different bacterium killing functions, effective components such as antibiotics and hormones, high cost prices, poor stability, toxicity and resistance to drugs, can cause a certain damage to the skin, are not capable of eliminating odor, and have high recurrence rates. The nursing agent is pure natural plant essence, can remove peculiar smell and nourish the skin in sterilization and disease treatment, keep the normal physiological environment of the skin, is safe, non-toxic and highly efficient and is suitable for people with different skin types and signs.
Cases of PRCA and of severe anemia, with or without other cytopenias that arise following the development of neutralizing antibodies to erythropoietin have been reported in the postmarketing setting in patients treated with Mircera. This has been reported predominantly in patients with CKD receiving ESAs by subcutaneous administration. PRCA was not observed in clinical studies of Mircera. 

PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which Mircera is not approved).

If severe anemia and low reticulocyte count develop during treatment with Mircera, withhold Mircera and evaluate patients for neutralizing antibodies to erythropoietin [see Warnings and Precautions (5.5)]. Serum samples should be obtained at least a month after the last Mircera administration to prevent interference of Mircera with the assay. Contact Vifor at 1-800-576-8295 to perform assays for binding and neutralizing antibodies. Permanently discontinue Mircera in patients who develop PRCA following treatment with Mircera or other erythropoietin protein drugs. Do not switch patients to other ESAs as antibodies may cross-react [see Adverse Reactions (6.2)].
Systems, methods, and instrumentalities are disclosed for using interrelated machine learning (ML) models (e.g., algorithms). The interrelated ML models may act collectively to perform complimentary portions of a surgical analysis. The ML models may be used at various locations. For example, ML models may be implemented in a facility network, a cloud network, an edge network, and/or the like. The location of the ML models may influence the type of data the ML models process. For example, ML models used outside a HIPAA boundary (e.g., cloud network) may process non-private and/or non-confidential information. The ML models may be used to feed their respective results into other ML models to provide a more complete result. Systems, methods, and instrumentalities are disclosed for aggregating and/or apportioning available surgical data into a more usable dataset for machine learning (ML) model (e.g., algorithm) interaction. A ML model may be more accurate and/or reliable if using complete and/or regular data. Aggregating and/or apportioning available surgical data may enable a more complete and/or regular dataset for ML model analysis. Systems, methods, and instrumentalities are disclosed for a surgical computing system with support for machine learning model interaction. Data exchange behavior between machine learning (ML) models and data storages may be determined and implemented. For example, data exchange may be determined based on privacy implications associated with a ML model and/or data storage. Data exchange may be determined based on processing goals associated with ML models.
Dizziness, drowsiness, light-headedness, staggering, ataxia and falling can occur, particularly in elderly or debilitated persons. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdosage, have been reported.

Flurazepam is a central nervous system (CNS) depressant and can impair daytime function even when used as prescribed. Prescribers should monitor for excess depressant effects, but impairment can occur in the absence of subjective symptoms, and may not be reliably detected by ordinary clinical exam (i.e., less than formal psychomotor testing). While pharmacodynamic tolerance or adaptation to some adverse depressant effects of flurazepam may develop, patients using flurazepam should be cautioned against driving or engaging in other hazardous activities or activities requiring complete mental alertness.

Additive effects occur with concomitant use of other CNS depressants (e.g., other benzodiazepines, opioids, tricyclic antidepressants, alcohol). Downward dose adjustment of flurazepam and concomitant CNS depressants should be considered. The potential for adverse drug interactions continues for several days following discontinuation of flurazepam, until serum levels of psychoactive metabolites decline.

Use of flurazepam with other sedative-hypnotics is not recommended. Alcohol generally should not be used during treatment with flurazepam. The risk of next-day psychomotor impairment is increased if flurazepam is taken with less than a full night of sleep remaining (7 to 8 hours); if higher than the recommended dose is taken; if coadministered with other CNS depressants [see Dosage and Administration ( 2)]. 

Because flurazepam can cause drowsiness and a decreased level of consciousness, patients, particularly the elderly, are at higher risk of falls.
Neonates gestational age \>35 weeks or older. Collect whole blood sample via heel prick or, where an in dwelling line already exists, via arterial/umbilical draw.
503,302. Distemper serum. WUNSCHHEIM, 0. R. VON. Oct. 26, 1938, No. 31011. Convention date, Oct. 26, 1937. [Class 81 (i)] A curative and preventive serum for distemper is-obtained by injecting into animals stocks of bacteria belonging partly to the paratyphus enteritis group, partly to the coli group and partly to the intermedius group, in the form bf a vaccine and obtaining the serum from the blood of the animal in the usual manner. The vaccine may consist of the dead bacteria or of the toxins obtained by filtering a culture of the bacteria.
Laryngopharyngeal reflux (LPR) is a disorder caused by acid-induced damage to the larynx and pharynx (voice box and throat). The standard care for persons with this disorder is treatment with highly potent anti-acid medications (proton pump inhibitors - Prevacid is one of these. NExium, Aciphex and Prilosec are others). These medications are currently approved by the FDA for the treatment of gastroesophageal reflux disease (GERD). Although the use of these medications in persons with LPR is widely accepted and sanctioned, this research is being done because these medications are not currently approved by the FDA for this use. The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).
Face-selective regions in the human ventral occipito-temporal cortex (VOTC) have been defined for decades mainly with functional magnetic resonance imaging. This face-selective VOTC network is traditionally divided in a posterior 'core' system thought to subtend face perception, and regions of the anterior temporal lobe as a semantic memory component of an extended general system. In between these two putative systems lies the anterior fusiform gyrus and surrounding sulci, affected by magnetic susceptibility artifacts. Here we suggest that this methodological gap overlaps with and contributes to a conceptual gap between (visual) perception and semantic memory for faces. Filling this gap with intracerebral recordings and direct electrical stimulation reveals robust face-selectivity in the anterior fusiform gyrus and a crucial role of this region, especially in the right hemisphere, in identity recognition for both familiar and unfamiliar faces. Based on these observations, we propose an integrated theoretical framework for human face (identity) recognition according to which face-selective regions in the anterior fusiform gyrus join the dots between posterior and anterior cortical face memories.
Early identification of patients at high risk of cardiac surgery-associated acute kidney injury (CSA-AKI) is crucial for its prevention. We aimed to leverage perioperative clinical and intraoperative biosignal data to develop machine learning models that predict CSA-AKI. We introduced a novel approach for extracting relevant features from high-resolution intraoperative biosignals to reflect the patient's baseline status, the extent of unfavorable conditions encountered intraoperatively, and data variability. We developed XGBoost models from 2,003 patients across three consecutive perioperative phases using: 1) only preoperative, 2) pre- and intraoperative, and 3) pre-, intra-, and postoperative variables. The predictive performance progressively improved throughout the three consecutive perioperative phases (e.g., AUROC of 0.767 to 0.797 and 0.840), all surpassing the Thakar Score's performance. According to the SHAP method, intraoperative perfusion pressure was most important in the prediction, highlighting the importance of intraoperative patient management and the use of high-resolution biosignal data in predictive modeling to analyze hemodynamic fluctuations during surgery. Early postoperative biomarkers were also important predictors, highlighting the importance of intensified monitoring early after surgery.
The intended intervention consists of a leucine-rich protein-caloric supplement provided by the Enhanced Medical Nutrition®. The product contains 25 g protein and 3 g Leucine per serving (total caloric value: 160 Kcal.) to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home (Appendix A).
Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) test product, treatment 2= Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) reference product.
The invention relates to the technical field of molecular biology and biological medicines, and particularly relates to application of gRNA sequences and combination thereof based on a CRISPR system in treatment on hepatitis B virus. According to the method disclosed by the invention, eight types of guidance RNAs (gRNA) are designed according to design rules of CRISPR gRNA and a conservative region of different genotypes of HBV sequences, and the eight types of guidance RNAs are structured on a PX330 expression vector. By utilizing the eight gRNAs in a cell model, a mouse model and a CRISPR/Cas9 system guided by combination of the cell model and the mouse model, the expression and replication of the hepatitis B virus can be effectively inhibited. By united application of a plurality of gRNAs, a better effect can be achieved, and different genotypes of HBV replication can be better inhibited. The system has the characteristics of being easy to operate, high in inhibition efficiency on HBV replication and applicable to various genotypes. Therefore, the gRNA and the combination thereof related to the invention are expected to be applied in preparation of a novel drug for treating the hepatitis B virus.
What is described herein is a fine particulate, crosslinked cationic microgel which is capable of adsorbing up to 200 times its dry gel weight of water, and which has a viscosity of 5870 cps in water at a pH of 2.8 adjusted with a divalent or trivalent acid, at a copolymer concentration of about 1 %. The microgel includes, by weigth, about 5-95 %, preferably 50 % of a water soluble monomer which is vinyl pyrrolidone (VP), and about 5-95 %, preferably 50 %, of a water soluble cationic monomer which is 3-dimethylaminopropyl-(meth)acrylamide (DMAPMA) and a low crosslinker content, e.g. about 0.2 %. The copolymers are made by a solution polymerization process from a mixture of VP and DMAPMA, crosslinker, solvent and initiator. The invention also describes hair care composition which include, by weight, about 0.01-5 % of such microgel polymers, and water, at a low pH, which exhibit conditioning and styling of the microgel copolymer and water. In shampoo formulations, optionally an anionic surfactant is included.